Fig. 2: Clinical outcomes.
From: Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
a–c, Swimmers’ plots depicting DORs after mTAA infusions in patients treated in arms A (a), B (b) and C (c). The timing of infusions is indicated. d–f, Kaplan–Meier survival analysis. Survival estimates are shown for OS (d, all arms; n = 37), EFS (e, all arms; n = 37) and RFS (f; arm C only, resected patients; n = 9). F/U, follow-up, between 1 month and 12 months after the last infusion.
